RxDoctor Payments Data

Sherry Shire-Misnik

Nurse Practitioner · Trevose, PANPI 1770721433

Payments from drug & device makers

$7,294in general payments, 2019–2025

Across 229 payments — averaging $31.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$882
  • Novo Nordisk$736
  • Lilly USA, LLC$688
  • Amgen$588
  • AbbVie$563
  • Pfizer$532
  • plus $3K from 35 others

What the payments were for

  • Food & beverage$7,294100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,294 in reported general payments places this provider in the 95th percentile of 4,059 nurse practitioner providers in Pennsylvania.

See all nurse practitioner providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$45,719
Medicare patients
260
Services billed
545

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide43$40,914
JardianceEmpagliflozin33$35,461
EliquisApixaban40$32,113
FarxigaDapagliflozin Propanediol24$23,932
TrulicityDulaglutide13$21,483
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$18,531
JanuviaSitagliptin Phosphate17$18,141
XareltoRivaroxaban13$16,147
Spiriva HandihalerTiotropium Bromide14$10,230
JanumetSitagliptin Phos/Metformin Hcl13$9,141
VascepaIcosapent Ethyl20$7,239
Breo ElliptaFluticasone/Vilanterol12$5,405
Atorvastatin Calcium274$4,101
Rosuvastatin Calcium186$3,453
Levothyroxine Sodium209$2,945

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$736$40,91443 claims
Boehringer IngelheimJardiance$162$35,46133 claims
PfizerEliquis$532$32,11340 claims
MerckJanuvia, Janumet$32$27,28230 claims
GSKTrelegy Ellipta, Breo Ellipta$41$23,93624 claims
AstraZenecaFarxiga$882$23,93224 claims
Lilly USA, LLCTrulicity, Olanzapine$688$23,22730 claims
Johnson & JohnsonXarelto$268$16,14713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,059 nurse practitioner providers in Pennsylvania.

Other nurse practitioner in Trevose

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →